SCHEMBL24910470

SCHEMBL24910470

Cc1nc2cc(C(C)(C)C)c(C(C)(C)C)cc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
KDM4E B2RXH2 5/20 0.51
POLB P06746 4/20 0.51
HPGD P15428 3/20 0.51
ALDH1A1 P00352 5/20 0.47
GAA P10253 2/20 0.45
HSD17B10 Q99714 1/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
HSP90AA1 P07900 1/20 0.42
ESR2 Q92731 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
RAB9A P51151 4/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
NPC1 O15118 3/20 0.39
PKM P14618 1/20 0.39
CACNA1H O95180 1/20 0.39
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10299149 0.85 MAPT (0.50) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL13041691 0.80 ALDH1A1 (0.59) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL12213872 0.78 MAPT (0.68) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL21983963 0.76 MAPT (0.60) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL10146527 0.74 MAPT (0.58) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL27074027 0.74 MAPT (0.58) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL1038167 0.74 FABP6 (0.63) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL13947194 0.74 ALDH1A1 (0.53) MAPTKDM4EPOLBHPGDALDH1A1
SCHEMBL805057 0.73 GAA (0.68) MAPTALDH1A1GAAHSD17B10TDP1
SCHEMBL4393880 0.73 MAPT (0.50) MAPTKDM4EPOLBHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019280-A1 SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, CDV3, HCCS MAPT 3601/4885KDM4E 1888/4885POLB 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.